Role of Vif in HIV-1 Replication/AIDS

Vif 在 HIV-1 复制/艾滋病中的作用

基本信息

  • 批准号:
    6346452
  • 负责人:
  • 金额:
    $ 5.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-05-01 至 2002-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (provided by applicant) The HIV-1 Vif gene is essential for infectious virus production by nonpermissive cells (NP), which include CD4-positive T-lymphocytes and macrophages and some leukemic T-cell lines such as HUT78 and MT-2, but is irrelevant in other cell lines that are termed permissive (P). NP cells can be infected with Vif-deleted HIV-1 derived from P cells, but the infected NP cells release only noninfectious virions. These noninfectious virions cannot be rescued by Vif expression in target cells, and they are believed to have a defect in their genomic RNA or core proteins that reduces the efficiency of reverse transcription. We and another laboratory recently performed complementation studies which showed the dominance of the NP phenotype in PxNP heterokaryons, suggesting that NP cells contain a factor that can inactivate HIV-1 and that this factor is counteracted by Vif. Using a human lymphocyte cDNA library in a yeast two-hybrid screen with Vif as bait, we have now identified the interferon-inducible protein Sp140 as an excellent candidate for this NP factor. Briefly, Sp140 occurs in all tested NP cells but not in P cells. Sp140 occurs in nuclear bodies (NBs) that contain several proteins covalently modified by addition of the ubiquitin-related protein Sumo-1. Expression of Sp140 in Hela-CD4 cells induces sumoylation of at least one protein, and coexpression of Vif blocks this induction. Thus, Vif counteracts at least one biochemical effect of Sp140. We propose: (i) Analyze Sp140 isoforms and related proteins for their abilities to inactivate Vif-deleted H1V-1. (ii) Identify active sites for interaction of Vif with Sp140 and with other potential partners identified by our two-hybrid screen. (iii) By two-dimensional electrophoresis, identify all sumoylated and non-sumoylated proteins induced in P cells by Sp140, and determine how Vif influences these inductions. Similarly, determine whether Vif expession in NP cells alters protein sumoylation and whether Vif-deleted HIV-1 made in P or NP cells contains any sumoylated protein. (iv) Interestingly, the herpes simplex virus type 1 ICPO protein targets NBs and specifically causes the elimination of some sumoylated NB proteins, and proteins encoded by CMV, EBV, adenoviruses and arenaviruses appear to have similar activities. Determine whether expression of these other viral proteins converts NP cells to P. This project seeks to identify Sp140 or another protein in the natural cellular targets of HIV-1 that could potentially eradicate infection were it not neutralized by Vif. This work may unveil a novel target for drug development in AIDS.
描述:(由申请人提供)HIV-1 Vif基因对于

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Kabat其他文献

David Kabat的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Kabat', 18)}}的其他基金

Drug development for Vif-APOBEC3G in HIV-1/AIDS
Vif-APOBEC3G 治疗 HIV-1/AIDS 的药物开发
  • 批准号:
    7061978
  • 财政年份:
    2005
  • 资助金额:
    $ 5.25万
  • 项目类别:
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Vif-APOBEC3G 治疗 HIV-1/AIDS 的药物开发
  • 批准号:
    7152570
  • 财政年份:
    2005
  • 资助金额:
    $ 5.25万
  • 项目类别:
Drug development for Vif-APOBEC3G in HIV-1/AIDS
Vif-APOBEC3G 治疗 HIV-1/AIDS 的药物开发
  • 批准号:
    7321662
  • 财政年份:
    2005
  • 资助金额:
    $ 5.25万
  • 项目类别:
Role of Vif in HIV-1 Replication/AIDS
Vif 在 HIV-1 复制/艾滋病中的作用
  • 批准号:
    6511565
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Role of Vif in HIV-1 Replication/AIDS
Vif 在 HIV-1 复制/艾滋病中的作用
  • 批准号:
    6742442
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Role of Vif in HIV-1 Replication/AIDS
Vif 在 HIV-1 复制/艾滋病中的作用
  • 批准号:
    6408784
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
Vif 变体和 APOBEC3 在 HIV-1/AIDS 中的作用
  • 批准号:
    7414558
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Role of Vif in HIV-1 Replication/AIDS
Vif 在 HIV-1 复制/艾滋病中的作用
  • 批准号:
    6891314
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Role of Vif in HIV-1 Replication/AIDS
Vif 在 HIV-1 复制/艾滋病中的作用
  • 批准号:
    6632461
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
Vif 变体和 APOBEC3 在 HIV-1/AIDS 中的作用
  • 批准号:
    7166732
  • 财政年份:
    2001
  • 资助金额:
    $ 5.25万
  • 项目类别:

相似海外基金

DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB
直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血
  • 批准号:
    6304094
  • 财政年份:
    1999
  • 资助金额:
    $ 5.25万
  • 项目类别:
DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB
直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血
  • 批准号:
    6263933
  • 财政年份:
    1998
  • 资助金额:
    $ 5.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了